Adeona, Intrexon ink deal for DNA-based therapy in PAH treatment

The development of therapeutic will make use of Intrexon’s UltraVector platform and RheoSwitch Therapeutic System.

Adeona will utilize Intrexon’s transgene engineering platform for the controlled, precise and continuous in vivo cellular production of prostaglandin synthase (PGIS), a specific effector enzyme that regulates the production of prostacyclin.

Prostacyclin is a short-acting vasodilator and inhibitor of platelet aggregation that has demonstrated a survival benefit in primary pulmonary hypertension patients.

As per the agreement, Intrexon will take up the charge of certain aspects of manufacturing and technology discovery efforts.

Adeona will be responsible for conducting preclinical and clinical development of candidates, as well as for other aspects of manufacturing and the commercialization of the candidate product.